$BOTH
BIOETHICS LTD

2024 Q2 Form 10-K Financial Statement

#000109690624000792 Filed on April 11, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.98K $13.60K $50.44K
YoY Change 52.81% 6.64%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $22.98K $13.60K $50.44K
YoY Change 55.14% 52.81% 6.64%
Operating Profit -$22.98K -$50.44K
YoY Change 55.14% 6.64%
Interest Expense $12.95K -$10.80K $46.71K
YoY Change 7.96% -8.47% 1.76%
% of Operating Profit
Other Income/Expense, Net -$12.95K -$46.71K
YoY Change 7.96% 1.76%
Pretax Income -$35.93K -$24.40K -$97.15K
YoY Change 34.02% 17.87% 4.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$35.93K -$24.40K -$97.15K
YoY Change 34.02% 17.87% 4.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$0.03 -$0.02 -$0.09
COMMON SHARES
Basic Shares Outstanding 1.135M shares 1.135M shares 1.135M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.17K $140.00 $140.00
YoY Change -53.33% -53.33%
Cash & Equivalents $10.17K $138.00 $140.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.17K $138.00 $140.00
YoY Change 2049.68% -53.22% -53.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $10.17K $138.00 $140.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $10.17K $138.00 $140.00
YoY Change 2049.68% -53.22% -53.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $150.7K $122.4K $136.9K
YoY Change 34.92% 22.08% 25.86%
Accrued Expenses $108.9K $98.36K $196.8K
YoY Change 21.67% 24.23% 31.13%
Deferred Revenue
YoY Change
Short-Term Debt $491.7K $442.7K $442.7K
YoY Change 5.27% 5.27%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $862.0K $776.4K $776.4K
YoY Change 18.08% 14.28% 14.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $862.0K $776.4K $776.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $862.0K $776.4K $776.4K
YoY Change 18.08% 14.28% 14.28%
SHAREHOLDERS EQUITY
Retained Earnings -$1.353M -$1.278M
YoY Change 9.93% 8.23%
Common Stock $1.135K $1.135K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$851.9K -$776.3K -$776.3K
YoY Change
Total Liabilities & Shareholders Equity $10.17K $138.00 $140.00
YoY Change 2049.68% -53.22% -53.33%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$35.93K -$24.40K -$97.15K
YoY Change 34.02% 17.87% 4.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$33.02K -$6.200K -$22.31K
YoY Change 87.31% -13.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.10K 5.850K $22.15K
YoY Change 91.8% -12.1%
NET CHANGE
Cash From Operating Activities -33.02K -6.200K -$22.31K
Cash From Investing Activities 0.000 $0.00
Cash From Financing Activities 43.10K 5.850K $22.15K
Net Change In Cash 10.08K -350.0 -$157.00
YoY Change 34.62% -64.24%
FREE CASH FLOW
Cash From Operating Activities -$33.02K -$6.200K -$22.31K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Entity File Number
EntityFileNumber
33-55254-41
CY2023 dei Entity Registrant Name
EntityRegistrantName
BIOETHICS, LTD.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0485312
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1661 Lakeview Circle
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ogden
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84403
CY2023 dei City Area Code
CityAreaCode
801
CY2023 dei Local Phone Number
LocalPhoneNumber
399-3632
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
27352 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1135194 shares
CY2023 dei Auditor Firm
AuditorFirmId
318
CY2023 dei Auditor Name
AuditorName
L J Soldinger Associates, LLC
CY2023 dei Auditor Location
AuditorLocation
Deer Park, IL
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
295 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
138 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295 usd
CY2023Q4 us-gaap Assets
Assets
138 usd
CY2022Q4 us-gaap Assets
Assets
295 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
122400 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100265 usd
CY2023Q4 fil Accounts Payable Related Party
AccountsPayableRelatedParty
14500 usd
CY2022Q4 fil Accounts Payable Related Party
AccountsPayableRelatedParty
8500 usd
CY2023Q4 fil Accrued Interest Related Parties
AccruedInterestRelatedParties
98406 usd
CY2022Q4 fil Accrued Interest Related Parties
AccruedInterestRelatedParties
70883 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
98363 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79179 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2023Q4 fil Notes Payable Related Parties
NotesPayableRelatedParties
247734 usd
CY2022Q4 fil Notes Payable Related Parties
NotesPayableRelatedParties
225584 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776403 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
679411 usd
CY2023Q4 us-gaap Liabilities
Liabilities
776403 usd
CY2022Q4 us-gaap Liabilities
Liabilities
679411 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1277879 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1180730 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50442 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47303 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
50442 usd
CY2023 us-gaap Interest Expense
InterestExpense
46707 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
47303 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-50442 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-47303 usd
CY2022 us-gaap Interest Expense
InterestExpense
45900 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-46707 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-45900 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-97149 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93203 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-97149 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-93203 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1135194 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-585913 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-93203 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-97149 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-97149 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-93203 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
22135 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
20664 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
6000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1000 usd
CY2023 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
27523 usd
CY2022 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
25336 usd
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
19184 usd
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
20564 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22307 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25639 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000 usd
CY2023 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
22150 usd
CY2022 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
15200 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22150 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25200 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-157 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-439 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
734 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295 usd
CY2023 us-gaap Interest Paid
InterestPaid
0 usd
CY2022 us-gaap Interest Paid
InterestPaid
0 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
261000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
241000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
28000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
28000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
289000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
269000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
20000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
20000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-20000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-20000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1278000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1277879 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-97149 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-93203 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14769 shares
CY2022Q4 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
14406 shares
CY2023Q4 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1149963 shares
CY2022Q4 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
1149600 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares

Files In Submission

Name View Source Status
0001096906-24-000792-index-headers.html Edgar Link pending
0001096906-24-000792-index.html Edgar Link pending
0001096906-24-000792.txt Edgar Link pending
0001096906-24-000792-xbrl.zip Edgar Link pending
both-20231231.htm Edgar Link pending
both-20231231.xsd Edgar Link pending
both_ex31z1.htm Edgar Link pending
both_ex32z1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
both-20231231_cal.xml Edgar Link unprocessable
both-20231231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
both-20231231_pre.xml Edgar Link unprocessable
both-20231231_htm.xml Edgar Link completed
both-20231231_def.xml Edgar Link unprocessable